Cargando…

Balancing Benefits and Risks: Do Inhaled Corticosteroids Modify the Lung Microbiome?

Detalles Bibliográficos
Autores principales:	Singh, Shivani, Pragman, Alexa A., Segal, Leopoldo N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Thoracic Society 2021
Materias:	Editorials
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8759301/ https://www.ncbi.nlm.nih.gov/pubmed/34554893 http://dx.doi.org/10.1164/rccm.202109-2024ED

Ejemplares similares

Inhaled Corticosteroids and the Lung Microbiome in COPD
por: Keir, Holly R., et al.
Publicado: (2021)

Lung Allograft Dysfunction: Does Aspiration Hold the Key?
por: Pragman, Alexa A.
Publicado: (2022)

The dynamic lung microbiome in health and disease
por: Natalini, Jake G., et al.
Publicado: (2022)

COVID-19, Asthma, and Inhaled Corticosteroids: Another Beneficial Effect of Inhaled Corticosteroids?
por: Maes, Tania, et al.
Publicado: (2020)

Before and beyond Inhaled Corticosteroids
por: Vazquez Guillamet, Rodrigo
Publicado: (2020)

Risk of Pneumonia Associated With the Use of Inhaled Corticosteroids in Asthma
por: Kim, Sang-Heon
Publicado: (2019)

Inhaled Corticosteroids and Bronchiectasis: Friend or Foe?
por: Martinez-Garcia, Miguel Angel
Publicado: (2023)

Compare the Effect of Inhaled Corticosteroids and Systemic Corticosteroids on Sputum Microbiome of AECOPD
por: Ma, Nan, et al.
Publicado: (2021)

One More Time: The Impact of Inhaled Corticosteroid Withdrawal on IMPACT
por: Han, MeiLan K., et al.
Publicado: (2020)

The Lung Microbiome in Moderate and Severe Chronic Obstructive Pulmonary Disease
por: Pragman, Alexa A., et al.
Publicado: (2012)

Inhaled corticosteroids and COVID-19: a systematic review and clinical perspective
por: Halpin, David M.G., et al.
Publicado: (2020)

An overview of the benefits and drawbacks of inhaled corticosteroids in chronic obstructive pulmonary disease
por: Singh, Sonal, et al.
Publicado: (2010)

Size of Inhaled Corticosteroid and Small Airway Inflammation in Asthma
por: Park, Choon-Sik
Publicado: (2017)

Inhaled Corticosteroid Use in Early Childhood: A Risk for High Body Mass Index?
por: Permaul, Perdita, et al.
Publicado: (2021)

Balancing risk and benefit during coronavirus
por: Sehn, Laurie H.
Publicado: (2020)

Toward effective prescription of inhaled corticosteroids in chronic airway disease
por: Diamant, Zuzana, et al.
Publicado: (2018)

The Challenging Road of Moving from Association to Causation for Microbiome Research in Idiopathic Pulmonary Fibrosis
por: Segal, Leopoldo N., et al.
Publicado: (2019)

Inhaled Corticosteroids
por: Barnes, Peter J.
Publicado: (2010)

The efficacy and safety of inhaled corticosteroids: are we ignoring the potential advantages of ciclesonide?
por: van der Molen, Thys, et al.
Publicado: (2014)

The polyhedric reality of the interaction between COVID-19, asthma and inhaled corticosteroids
por: Gonzalez-Barcala, Francisco-Javier, et al.
Publicado: (2022)

Inhaled Corticosteroids for asthma treatment in India: An urgent and radical rethink needed
por: Sovani, Milind P., et al.
Publicado: (2022)

Inhaled Corticosteroids in Asthma and the Risk of Pneumonia
por: Kim, Min-Hye, et al.
Publicado: (2019)

Antenatal corticosteroids and COVID-19: balancing benefits and harms
por: Liauw, Jessica, et al.
Publicado: (2020)

The benefits of combined treatment with corticosteroids and long-acting beta agonists
por: Singh, Dave
Publicado: (2006)

Inhaled Corticosteroid Withdrawal in Chronic Obstructive Pulmonary Disease: Can IMPACT Help?
por: Suissa, Samy
Publicado: (2020)

Reigniting the TORCH: Chronic Obstructive Pulmonary Disease Mortality and Inhaled Corticosteroids Revisited
por: Calverley, Peter
Publicado: (2021)

Over-the-counter Dispensing: Widening Access to Inhaled Corticosteroid/Formoterol Reliever Therapy
por: Beasley, Richard, et al.
Publicado: (2022)

Trastuzumab cardiotoxiciy: the age-old balance of risk and benefit
por: Ewer, Michael S, et al.
Publicado: (2016)

Balancing risks and benefits of artificial intelligence in the health sector
por: Goodman, Kenneth, et al.
Publicado: (2020)

Neurosurgical innovation: balancing the risks and benefits of technical novelty
por: Cohen-Gadol, Aaron A.
Publicado: (2019)

Benefit-risk balance of COVID drugs. New prospects
por: Cracowski, Jean-Luc, et al.
Publicado: (2022)

From inhaler to lung: clinical implications of the formulations of ciclesonide and other inhaled corticosteroids
por: Nave, Ruediger, et al.
Publicado: (2013)

The airways microbiome of individuals with asthma treated with high and low doses of inhaled corticosteroids
por: Martin, Matthew J., et al.
Publicado: (2020)

Looking Higher: Is It Prime Time for the Oral–Lung Axis in HIV-related Lung Disease?
por: Huang, Yvonne J., et al.
Publicado: (2020)

Inhaled corticosteroids in COPD and the risk of serious pneumonia
por: Suissa, Samy, et al.
Publicado: (2013)

Inhaled Corticosteroids Is Not Associated with the Risk of Pneumonia in Asthma
por: Lee, Ye Jin, et al.
Publicado: (2023)

Lung microbiome and host immune tone in subjects with idiopathic pulmonary fibrosis treated with inhaled interferon-γ
por: Wang, Jing, et al.
Publicado: (2017)

Asthma and Therapeutics: Inhaled Corticosteroids, Corticosteroid Osteoporosis, and the Risk of Fracture in Chronic Asthma
por: Toogood, John H
Publicado: (2005)

Inhaled Bronchodilators and Corticosteroids in the Management of Bronchiolitis Obliterans due to Allogenic Hematopoietic Stem Cell Transplantation
por: Georgakopoulou, Vasiliki Epameinondas, et al.
Publicado: (2022)

Does the use of inhaled corticosteroids in asthma benefit lung function in the long-term? A systematic review and meta-analysis
por: Tan, Daniel J., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_mb8knh55bcnd24rit6hlitnse0